Compare MRVI & GLAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRVI | GLAD |
|---|---|---|
| Founded | 2014 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.6M | 482.1M |
| IPO Year | 2020 | N/A |
| Metric | MRVI | GLAD |
|---|---|---|
| Price | $3.61 | $21.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $4.58 | ★ $22.33 |
| AVG Volume (30 Days) | ★ 1.5M | 198.8K |
| Earning Date | 11-06-2025 | 11-17-2025 |
| Dividend Yield | N/A | ★ 9.23% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.55 |
| Revenue | ★ $192,435,000.00 | $89,122,000.00 |
| Revenue This Year | N/A | $13.04 |
| Revenue Next Year | $9.04 | $9.55 |
| P/E Ratio | ★ N/A | $8.42 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.67 | $18.76 |
| 52 Week High | $6.21 | $30.43 |
| Indicator | MRVI | GLAD |
|---|---|---|
| Relative Strength Index (RSI) | 54.00 | 58.48 |
| Support Level | $3.50 | $21.27 |
| Resistance Level | $3.95 | $21.73 |
| Average True Range (ATR) | 0.18 | 0.34 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 46.46 | 52.84 |
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.